Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164735 | 0.75 | CYP1A2 (0.55) | TAAR1GAAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL2475493 | 0.75 | GRIN2D (0.53) | TAAR1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL3176867 | 0.75 | DYRK1A (0.39) | TAAR1GAAHTTKDM4EALDH1A1 | |
| SCHEMBL2469604 | 0.75 | ADRA2A (0.44) | ADRA2AADRA1AIDO1TDO2 | |
| SCHEMBL3155805 | 0.74 | TAAR1 (0.42) | TAAR1KDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL954052 | 0.73 | ADRA2A (0.55) | TAAR1GAAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL7371933 | 0.73 | TAAR1 (0.45) | TAAR1SMN1; SMN2ADRA2A | |
| SCHEMBL3285266 | 0.72 | CYP2D6 (0.51) | TAAR1IDO1TDO2 | |
| SCHEMBL12706123 | 0.72 | IDO1 (0.52) | TAAR1GAASMN1; SMN2ALDH1A1IDO1 | |
| SCHEMBL632198 | 0.71 | HRH4 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HTR2C, AHR, HAX1 | TAAR1 60/4885GAA 4510/4885HTT 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.